Human trials of an innovative treatment for rheumatoid arthritis developed by Â鶹´«Ã½Ó³» of Queensland have begun in Brisbane.
DEN-181, a vaccine-style treatment referred to as an ’immunotherapy’, targets the underlying cause of the disease rather than treating its inflammatory symptoms.
Patient trials at a clinical research facility at the Princess Alexandra Hospital began last week.
Â鶹´«Ã½Ó³»’s research team, led by , discovered the body’s immune system could be ‘re-educated’ to turn off, rather than react to a self-antigen responsible for autoimmune disease like rheumatoid arthritis. This led to the development of DEN-181.
DEN-181 is being commercialised by , a start-up company of , Â鶹´«Ã½Ó³»’s commercialisation company.
UniQuest CEO Dr Dean Moss said the first-in-human trial was a momentous step towards making the breakthrough research discovery a treatment reality.
“This is an important milestone in developing a new medicine for the millions of people affected by this debilitating disease which destroys joints, causes cardiovascular complications and can reduce life-span,” he said.
Professor Thomas, who is also Dendright’s Chief Scientific Officer, said the phase 1b clinical trial was the bridge to bringing scientific data into clinical practice.
“The study team will be monitoring and assessing DEN-181 safety and immunological response in patients and we thank the participating patients and referring rheumatologists,” she said.
Â鶹´«Ã½Ó³» Advancement Director of Development and Philanthropy Andrew Pentland said Arthritis Queensland had been an important supporter of Â鶹´«Ã½Ó³»’s translational research and approaches to understanding disease biology since the early 1990s.
“Arthritis Queensland has provided philanthropic funding for the Arthritis Queensland Chair of Rheumatology at Â鶹´«Ã½Ó³» over many years,” he said.
“This is a great example of how a philanthropic partnership can help drive important research outcomes for the benefit of community.”
Professor Thomas is the inaugural recipient of the Arthritis Queensland Chair of Rheumatology at Â鶹´«Ã½Ó³».
Dendright entered into a research collaboration and option to license agreement with US-based Janssen Biotech, Inc. () in 2013.
This year Janssen agreed to provide additional funding to support further research, including the first-in-human safety trial and tolerability study that began in Brisbane last week.
Funding for the clinical program is also being provided by not-for-profit organisation .
Further details of the study including patient eligibility criteria are available at using search term ‘Dendright’. Enquiries regarding study criteria can also be directed to joanne.tesiram@health.qld.gov.au.
Media: UniQuest, Danielle Koopman, +61 409 767 199; Dendright, Helen Roberts, +61 419 657 504.
